XL-228

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameXL-228
Drug Alias NameXL-228
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSRC inhibitorsBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase SRC inhibitors
TargetsInsulin-like growth factor I receptorBcr-Abl tyrosine kinaseTyrosine-protein kinase SRC
Therapy Area/IndicationsLymphomaLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesExelixis Inc
Active IndicationsN/A
Inactive IndicationsLymphomaLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A